Literature DB >> 12447905

Structurally adaptive hot spots at a protein interaction interface on TRAF3.

Kathryn R Ely1, Chenglong Li.   

Abstract

Tumor necrosis factor (TNF) signaling is controlled by receptors and intracellular signaling pathways that activate the NF-kappaB transcription factor. The resulting signals elicit immune responses and have important implications for disorders such as autoimmunity or allergic reactions. TNF-receptor-associated factors (TRAFs) bind to the cytoplasmic portion of TNFRs as well as downstream regulators and thus are co-inducers of the signal transduction. TRAF3 binds to diverse receptors and regulators by accomodating a conserved motif that is embedded in completely different structural frameworks. Thus, the protein-protein contact region on TRAF3 represents a binding interface that is structurally and functionally adaptive. In this report, three 'hot spots' at the TRAF3 protein-interaction interface are defined that provide the principal contact regions for different binding partners. The side-chains of residues at these 'hot spots' are flexible and undergo movements on binding the different partners. These side chain rearrangements provide a structural adaptability that promotes interaction with a variety of distinct proteins. It is proposed that similar adaptive 'hot spots' are also present on the binding surfaces of TRAF1, TRAF2 and TRAF5. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12447905     DOI: 10.1002/jmr.589

Source DB:  PubMed          Journal:  J Mol Recognit        ISSN: 0952-3499            Impact factor:   2.137


  2 in total

1.  Single amino acid substitutions confer the antiviral activity of the TRAF3 adaptor protein onto TRAF5.

Authors:  Peng Zhang; Anna Reichardt; Huanhuan Liang; Roghiyh Aliyari; David Cheng; Yaya Wang; Feng Xu; Genhong Cheng; Yingfang Liu
Journal:  Sci Signal       Date:  2012-11-13       Impact factor: 8.192

2.  Hantavirus regulation of type I interferon responses.

Authors:  Valery Matthys; Erich R Mackow
Journal:  Adv Virol       Date:  2012-08-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.